Related Experiment Video
Updated: Feb 10, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Nature of tumour rejection antigens in ovarian cancer
Muzamil Y Want1, Amit A Lugade1, Sebastiano Battaglia1
1Center For Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract:
Major progress in the analysis of human immune responses to cancer has been made through the molecular characterization of human tumour antigens. The development of therapeutic strategies for eliciting immune-mediated rejection of tumours has accelerated due to the elucidation of the molecular basis for tumour cell recognition and destruction by immune cells. Of the various human tumour antigens defined to date in ovarian cancer, the cancer-testis (CT) family of antigens have been studied extensively preclinically and clinically because of their testis-restricted expression in normal tissues and ability to elicit robust immune responses. Recent developments in cancer sequencing technologies offer a unique opportunity to identify tumour mutations with the highest likelihood of being expressed and recognized by the immune system. Such mutations, or neoantigens, could potentially serve as specific immune targets for T-cell-mediated destruction of cancer cells. This review will highlight current work in selecting tumour rejection antigens in ovarian cancer for improving the efficacy of immunotherapy.
Insights
Identifying cancer-testis antigens and neoantigens in ovarian cancer is key for developing effective immunotherapies. This research focuses on selecting tumor rejection antigens to enhance T-cell-mediated cancer cell destruction.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Molecular characterization of human tumor antigens has advanced cancer immunotherapy.
- Cancer-testis (CT) antigens are extensively studied in ovarian cancer due to their immunogenicity and restricted expression.
- Elucidating tumor recognition mechanisms accelerates the development of immune-mediated tumor rejection strategies.
Purpose of the Study:
- To review current strategies for selecting tumor rejection antigens in ovarian cancer.
- To highlight the potential of neoantigens as specific immune targets for ovarian cancer immunotherapy.
- To improve the efficacy of immunotherapy by identifying optimal immune targets.
Main Methods:
- Review of preclinical and clinical studies on cancer-testis antigens in ovarian cancer.
- Analysis of recent advancements in cancer sequencing technologies for neoantigen identification.
- Evaluation of methods for selecting tumor mutations likely to be recognized by the immune system.
Main Results:
- Cancer-testis antigens are promising targets for ovarian cancer immunotherapy.
- Tumor mutations (neoantigens) identified through advanced sequencing can serve as specific immune targets.
- Selection of appropriate tumor rejection antigens is crucial for enhancing immunotherapy efficacy.
Conclusions:
- Targeting cancer-testis antigens and neoantigens holds significant potential for ovarian cancer treatment.
- Advances in sequencing technologies enable precise identification of targets for T-cell-mediated tumor destruction.
- Further research in selecting tumor rejection antigens will improve immunotherapy outcomes in ovarian cancer.
Related Concept Videos
Nature and Nurture
What is Natural Selection?
Hypothesis: Accept or Fail to Reject?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
Quantifying and Rejecting Outliers: The Grubbs Test
Ovarian Cycle
Chirality in Nature

